Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc
Your view on AVDL
Overview
What the company does, where it operates, and who runs it.
About Avadel Pharmaceuticals plc
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Gregory J. Divis Jr.
- Headquarters
- 10 Earlsfort Terrace, Dublin, IE
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Gregory J. Divis Jr.
- Headquarters
- 10 Earlsfort Terrace, Dublin, IE
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Avadel Pharmaceuticals plc from FRC's valuation model, read against the market price. AVDL last traded at $21.64, 216.0× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Avadel Pharmaceuticals plc. Starting points for Avadel Pharmaceuticals plc: P/E 216.0, EPS $0.10, beta 1.31 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Avadel Pharmaceuticals plc. Avadel Pharmaceuticals plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Avadel Pharmaceuticals plc. Trailing twelve-month EPS for Avadel Pharmaceuticals plc stands at $0.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$22.50
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy8
- Hold6
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2025 | Next QtrMar 2026 | Current YearFY Dec 2025 | Next YearFY Dec 2026 |
|---|---|---|---|---|
| Avg. estimate | $0.05 | $0.12 | $0.13 | $0.77 |
| Low estimate | $0.02 | $0.04 | -$0.02 | $0.55 |
| High estimate | $0.09 | $0.19 | $0.27 | $1.08 |
| No. of analysts | 6 | 4 | 6 | 6 |
| Year-ago EPS | -$0.05 | -$0.05 | -$0.511 | — |
| Growth | +196.0% | +343.1% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2025 | Next QtrMar 2026 | Current YearFY Dec 2025 | Next YearFY Dec 2026 |
|---|---|---|---|---|
| Avg. estimate | $79.92M | $78.11M | $277.47M | $355.71M |
| Low estimate | $75.75M | $68.19M | $271.10M | $349.16M |
| High estimate | $82.20M | $84.18M | $281.99M | $372.95M |
| No. of analysts | 5 | 5 | 5 | 6 |
| Year-ago revenue | $50.41M | $52.51M | $169.12M | — |
| Growth | +58.5% | +48.8% | +64.1% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 14, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Avadel Pharmaceuticals plc. Avadel Pharmaceuticals plc has reported as a listed company since 1996. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ALVOAlvotechDrug Manufacturers - Specialty & Generic$1.5B
- ANIPANI Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$1.6B
- BGMBGM Group Ltd.Drug Manufacturers - Specialty & Generic$100M
- EVOEvotec SEDrug Manufacturers - Specialty & Generic$561M
- GRDNGuardian Pharmacy Services, Inc.Medical - Care Facilities$3.1B
- MDPediatrix Medical Group, Inc.Medical - Care Facilities$2.4B
- OGNOrganon & Co.Drug Manufacturers - General$3.7B
- PAHCPhibro Animal Health CorporationDrug Manufacturers - Specialty & Generic$1.5B
More Drug Manufacturers - Specialty & Generic companies
- USMJNorth American Cannabis Holdings, Inc.OTC$137,858
- VDRMViaDerma, Inc.OTC$493,484
- VENI.CNVencanna Ventures Inc.CNQ$1M
- VEXT.CNVext Science, Inc.CNQ$59M
- VEXTFVext Science, Inc.OTC$44M
- VIBE.CNVibe Growth CorporationCNQ$647,819
- VIBEFVibe Growth CorporationOTC$431,880
- VIT.AXVitura Health LimitedASX
- VIVXFAvivagen Inc.OTC$7,769
- VLS.AXVita Life Sciences LimitedASX
- VM.VVoyageur Pharmaceuticals Ltd.TSXV$23M
- VPHIFValeo Pharma Inc.OTC$9,866
ETFs holding Avadel Pharmaceuticals plc
% of the fund
- GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETF$1.0B in assets
- FSMLFranklin Small Cap Enhanced ETF$147M in assets0.01%
- FLQSFranklin U.S. Small Cap Multifactor Index ETF$50M in assets0.01%
Largest holders first, then the funds most concentrated in AVDL.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Avadel Pharmaceuticals plc, and how their positions are changing. At a $2.12B market value, institutional positions materially move Avadel Pharmaceuticals plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Avadel Pharmaceuticals plc executives and directors. Shares of Avadel Pharmaceuticals plc have traded between $6.38 and $23.57 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Avadel Pharmaceuticals plc. Coverage tracks Avadel Pharmaceuticals plc within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Avadel Pharmaceuticals plc.